Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy.

INTRODUCTION We aimed to investigate the effect of radiotherapy (RT) in contemporary patients treated with radical prostatectomy (RP) compared to RP alone for non-metastatic prostate cancer (PCa) on the incidence of second primary cancers (SPCs). METHODS Within the Surveillance, Epidemiology, and End Results database (2004-2015), we identified patients with PCa as the only or first primary cancer, who underwent RP and RT or RP alone. Cumulative incidence plots and multivariable Cox regression models tested for SPC rate differences according to treatment type: RP and RT vs. RP alone. Subgroup analyses focused on pelvic, primary pelvic, and non-pelvic SPCs, as well as on late SPCs (>5 years after PCa diagnosis). RESULTS Of 152 161 patients, 7.1% (n=10 870) received RP and RT. Overall, 6.6 vs. 5.0% developed SPCs after RP and RT vs. RP alone, respectively (p<0.001). Cumulative incidence rates at 10 years after PCa diagnosis for RP and RT vs. RP were 12.0 vs. 8.7% (p<0.001), 2.0 vs. 1.2% (p<0.001), 2.1 vs. 1.3% (p<0.001), and 9.9 vs. 7.4% (p<0.001) for overall SPCs, primary pelvic SPCs, overall pelvic SPCs, and non-pelvic SPCs, respectively. Multivariable Cox regression models revealed an increased risk after RP and RT vs. RP alone for overall (hazard ratio [HR] 1.2; p<0.001), primary pelvic (HR 1.5; p<0.01), pelvic (HR1.4; p<0.001), non-pelvic (HR1.1; p<0.01), late overall (HR 1.2; p=0.01), and late non-pelvic SPCs (HR1.2; p=0.03). CONCLUSIONS RP with RT was associated with moderately increased risk of SPCs compared to RP alone. This observation should be thoroughly discussed at informed consent and considered during followup.

[1]  F. Saad,et al.  Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. , 2019, European urology focus.

[2]  A. Briganti,et al.  Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era , 2017, International Urology and Nephrology.

[3]  Cheng-Li Lin,et al.  A population-based cohort study. , 2015 .

[4]  K. Cooney,et al.  Risk of second primary tumors in men diagnosed with prostate cancer: A population‐based cohort study , 2014, Cancer.

[5]  Kun-jie Wang,et al.  Radiation-Induced Secondary Malignancy in Prostate Cancer: A Systematic Review and Meta-Analysis , 2014, Urologia Internationalis.

[6]  Nicholas G Zaorsky,et al.  Evolution of advanced technologies in prostate cancer radiotherapy , 2013, Nature Reviews Urology.

[7]  U. Capitanio,et al.  Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. , 2013, European urology.

[8]  I. Reis,et al.  Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data. , 2009, Urology.

[9]  F. Fazio,et al.  Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. , 2009, European urology.

[10]  Abigail Walton,et al.  Radiation-induced second malignancies. , 2008, Journal of palliative medicine.

[11]  Kara Hamilton,et al.  Second primary cancer after radiotherapy for prostate cancer--a seer analysis of brachytherapy versus external beam radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[12]  E. Messing,et al.  Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. , 2006, JAMA.

[13]  M. Marberger Postoperative Radiotherapy After Radical Prostatectomy: A Randomized Controlled Trial (EORTC trial 22911) , 2006 .

[14]  John E Tomaszewski,et al.  Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era , 2002, Cancer.